Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19

PHASE1,PHASE2

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped Stopped by the IP, because the first 6 patients recruited had died and it was unknown if it represented any safety risk or if the sample was insufficient to evaluate the study hypotesis.

Conditions

Acute Respiratory Distress Syndrome

Interventions

DRUG: Wharton's jelly derived Mesenchymal stem cells.
DRUG: Hydroxychloroquine, lopinavir/ritonavir or azithromycin and placebo (standard therapy)

Sponsor

BioXcellerator